Tigermed

Asia, Zhejiang, China, Hangzhou

Description

Tigermed is a contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.

Investor Profile

Tigermed has backed more than 5 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 20% of its total and boasts 6 exits across its portfolio.

Investment Focus Highlights

Concentrates on Series D, Series B, Series Unknown rounds (top funding stages).
Majority of deals are located in China.
Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.

Stage Focus

Series D (40%)
Series B (20%)
Series Unknown (20%)
Series C (20%)

Country Focus

China (100%)

Industry Focus

Biotechnology
Health Care
Pharmaceutical
Biopharma
Manufacturing
Oncology

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Tigermed frequently co-invest with?

China Capital Management

China Capital Management

Asia, Beijing, China, Beijing

Co-Investments: 1

Hudson Bay Capital Management

Hudson Bay Capital Management

North America, New York, United States, New York

Co-Investments: 1

C-Bridge Capital

C-Bridge Capital

North America, New York, United States, New York

Co-Investments: 1

RA Capital Management

RA Capital Management

North America, Massachusetts, United States, Boston

Co-Investments: 1

General Atlantic

General Atlantic

North America, New York, United States, New York

Co-Investments: 1

WuXi AppTec

Asia, Shanghai, China, Shanghai

Co-Investments: 1

YuanMing Capital

YuanMing Capital

Asia, Beijing, China, Haidian

Co-Investments: 1

CD Capital

Asia, Shanghai, China, Shanghai

Co-Investments: 1

Cormorant Capital

North America, New York, United States, New York

Co-Investments: 1

Qianhai Fund of Funds

Qianhai Fund of Funds

Asia, Fujian, China, Shanzhen

Co-Investments: 1

Which angels does Tigermed often collaborate with?

Shared Deals: 1

What are some of recent deals done by Tigermed?

Hangzhou, Zhejiang, China

Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.

BiotechnologyHealth CareOncologyPharmaceutical

Series DJul 13, 2021

Amount Raised: $100,000,000

Minhang, Shanghai, China

3D Medicines mission is to improve people’s health through cancer personalized diagnostics and treatment.

BiopharmaBiotechnologyHealth CarePharmaceutical

Series UnknownOct 9, 2020

Amount Raised: $140,000,000

Chengdu, Sichuan, China

Hinova Pharma is a pharmaceutical company.

Health CarePharmaceutical

Series COct 6, 2020

Amount Raised: $147,258,055

CANbridge Pharmaceuticals

Beijing, Beijing, China

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

BiotechnologyHealth CarePharmaceutical

Series DFeb 18, 2020

Amount Raised: $98,000,000

Suzhou, Jiangsu, China

CMAB BioPharm is a Biopharmaceutical Service Firm.

BiopharmaBiotechnologyManufacturing

Series BApr 2, 2018

Amount Raised: $34,000,000